PE20220596A1 - Anticuerpos que se unen a celulas cancerosas y que dirigen radionucleidos a dichas celulas - Google Patents

Anticuerpos que se unen a celulas cancerosas y que dirigen radionucleidos a dichas celulas

Info

Publication number
PE20220596A1
PE20220596A1 PE2021002320A PE2021002320A PE20220596A1 PE 20220596 A1 PE20220596 A1 PE 20220596A1 PE 2021002320 A PE2021002320 A PE 2021002320A PE 2021002320 A PE2021002320 A PE 2021002320A PE 20220596 A1 PE20220596 A1 PE 20220596A1
Authority
PE
Peru
Prior art keywords
domain
binding site
antibodies
cells
antibody
Prior art date
Application number
PE2021002320A
Other languages
English (en)
Inventor
Pablo Umana
Sabine Imhof-Jung
Alexander Haas
Christian Klein
Sofia Frost
Felix Bormann
Guy Georges
Sebastian Fenn
Florian Lipsmeier
Daniela Matscheko
Joerg Moelleken
Barbara Weiser
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20220596A1 publication Critical patent/PE20220596A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Referido a un conjunto de anticuerpos que comprende: i) un primer anticuerpo que se une a un antigeno expresado en la superficie de una celula objetivo, y que ademas comprende un dominio VH de un sitio de union a antigeno para un compuesto radiomarcado, pero que no comprende un dominio VL de un sitio de union a antigeno para el compuesto radiomarcado; y ii) un segundo anticuerpo que se une a dicho antigeno expresado en la superficie de la celula objetivo, y que ademas comprende un dominio VL de un sitio de union a antigeno para el compuesto radiomarcado, pero que no comprende un dominio VH del sitio de union a antigeno para el compuesto radiomarcado, donde dicho dominio VH del primer anticuerpo y dicho dominio VL del segundo anticuerpo son juntos capaces de formar un sitio de union a antigeno funcional para el compuesto radiomarcado. Tambien se refiere a un conjunto de acidos nucleicos que expresan dicho conjunto de anticuerpos, un vector de expresion o conjunto de vectores de expresion que comprende el conjunto de acidos nucleicos, una celula huesped o conjunto de celulas huesped que comprenden el vector.
PE2021002320A 2019-07-12 2020-07-10 Anticuerpos que se unen a celulas cancerosas y que dirigen radionucleidos a dichas celulas PE20220596A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19186135 2019-07-12
PCT/EP2020/069561 WO2021009047A1 (en) 2019-07-12 2020-07-10 Antibodies which bind to cancer cells and target radionuclides to said cells

Publications (1)

Publication Number Publication Date
PE20220596A1 true PE20220596A1 (es) 2022-04-22

Family

ID=67262219

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021002320A PE20220596A1 (es) 2019-07-12 2020-07-10 Anticuerpos que se unen a celulas cancerosas y que dirigen radionucleidos a dichas celulas

Country Status (17)

Country Link
US (1) US20220267463A1 (es)
EP (1) EP3997130A1 (es)
JP (1) JP2022540610A (es)
KR (1) KR20220034208A (es)
CN (1) CN114341188A (es)
AR (2) AR119382A1 (es)
AU (1) AU2020313285A1 (es)
BR (1) BR112022000481A2 (es)
CA (1) CA3143464A1 (es)
CL (1) CL2022000052A1 (es)
CO (1) CO2022001021A2 (es)
CR (1) CR20220061A (es)
IL (1) IL289040A (es)
MX (1) MX2022000379A (es)
PE (1) PE20220596A1 (es)
TW (1) TW202115117A (es)
WO (1) WO2021009047A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023000204A2 (pt) * 2020-07-10 2023-01-31 Hoffmann La Roche Conjunto de anticorpos, conjunto de ácidos nucleicos, vetor de expressão, célula hospedeira, métodos de pré-direcionamento de radioimunoterapia e direcionamento de um radioisótopo, ligante peptídico, proteína de múltiplos domínios e usos
WO2022152656A1 (en) * 2021-01-12 2022-07-21 F. Hoffmann-La Roche Ag Split antibodies which bind to cancer cells and target radionuclides to said cells

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5242824A (en) 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU757627B2 (en) 1997-06-24 2003-02-27 Genentech Inc. Methods and compositions for galactosylated glycoproteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DK1151010T3 (da) 1999-02-05 2006-01-09 Therapeutic Human Polyclonals Humane polyklonale antistoffer fra antigene ikke-humane dyr
JP2003505082A (ja) 1999-07-26 2003-02-12 ジェネンテック・インコーポレーテッド 新規なポリヌクレオチドとその使用法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
AU2001284703B2 (en) 2000-08-03 2007-03-22 Therapeutic Human Polyclonals Inc. Production of humanized antibodies in transgenic animals
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
JP4832719B2 (ja) 2002-04-09 2011-12-07 協和発酵キリン株式会社 ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
ES2362419T3 (es) 2002-04-09 2011-07-05 Kyowa Hakko Kirin Co., Ltd. Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa.
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
WO2003085107A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellules à génome modifié
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
PT1572744E (pt) 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
KR101292000B1 (ko) 2003-01-22 2013-08-01 로슈 글리카트 아게 융합 구성체와 Ｆｃ 수용체 결합 친화도 및 이펙터 기능이증가된 항체를 생성하기 위한 이의 용도
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
MXPA06000562A (es) 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
US7982011B2 (en) 2003-11-25 2011-07-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutated anti-cd22 antibodies and immunoconjugates
EP2360186B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101084317A (zh) 2004-10-22 2007-12-05 人类多克隆治疗公司 对内源免疫球蛋白表达的抑制
AU2006211037B2 (en) 2005-02-07 2012-05-24 Roche Glycart Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
CN103710371B (zh) 2005-08-03 2017-03-01 人类多克隆治疗股份有限公司 表达人源化免疫球蛋白的转基因动物中b细胞凋亡的抑制
US20090226444A1 (en) 2005-12-21 2009-09-10 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
JP5087625B2 (ja) 2006-09-01 2012-12-05 セラピューティック・ヒューマン・ポリクローナルズ・インコーポレーテッド 非ヒトトランスジェニック動物におけるヒトまたはヒト化免疫グロブリンの発現強化
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
EP2403530B1 (en) 2009-02-27 2016-05-11 Massachusetts Institute of Technology Engineered proteins with high affinity for dota chelates
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
LT2681244T (lt) 2011-03-02 2018-02-12 Roche Glycart Ag Cea antikūnai
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
RS56773B1 (sr) * 2012-01-13 2018-04-30 Univ Wuerzburg J Maximilians Dvojna bipartitna funkcionalna komplementacija izazvana antigenom
ES2676031T3 (es) 2012-02-15 2018-07-16 F. Hoffmann-La Roche Ag Cromatografía de afinidad basada en el receptor Fc
ES2775207T3 (es) 2013-02-26 2020-07-24 Roche Glycart Ag Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas específicas para CD3 y CEA
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
MX2017004001A (es) 2014-10-24 2017-06-30 Hoffmann La Roche Humanizacion de anticuerpos a base de angulo de interdominio de cadena pesada-cadena ligera (vh-vl).
SI3489256T1 (sl) 2014-11-14 2021-08-31 F. Hoffmann-La Roche Ag Molekule, ki vežejo antigen in vsebujejo trimer ligandov iz družine TNF
KR102668727B1 (ko) 2015-04-24 2024-05-28 제넨테크, 인크. 다중특이적 항원-결합 단백질
EP3356410B1 (en) 2015-10-02 2021-10-20 F. Hoffmann-La Roche AG Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
WO2017087789A1 (en) * 2015-11-19 2017-05-26 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US20210070846A1 (en) * 2017-12-21 2021-03-11 Gernot Stuhler Specific dosage regimen for hemibody therapy

Also Published As

Publication number Publication date
CO2022001021A2 (es) 2022-04-29
AR122930A1 (es) 2022-10-19
CN114341188A (zh) 2022-04-12
US20220267463A1 (en) 2022-08-25
MX2022000379A (es) 2022-02-10
TW202115117A (zh) 2021-04-16
AU2020313285A1 (en) 2022-02-17
WO2021009047A1 (en) 2021-01-21
KR20220034208A (ko) 2022-03-17
CA3143464A1 (en) 2021-01-21
AR119382A1 (es) 2021-12-15
BR112022000481A2 (pt) 2022-03-08
JP2022540610A (ja) 2022-09-16
IL289040A (en) 2022-02-01
EP3997130A1 (en) 2022-05-18
CL2022000052A1 (es) 2022-10-21
CR20220061A (es) 2022-04-20

Similar Documents

Publication Publication Date Title
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
CL2019000119A1 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123.
CL2023001082A1 (es) Constructos de anticuerpo biespecíficos que se ligan a células t
CL2017001328A1 (es) Anticuerpos heterodimericos que unen cd3 y antígenos tumorales
BR112019008861A2 (pt) anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3)
PE20180798A1 (es) Constructos de anticuerpos biespeficos que se unen a mesotelina y cd3
PE20180484A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t
PE20181152A1 (es) Constructos de anticuerpo biespecificos que se unen a dll3 ycd3
PE20180188A1 (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
PE20220596A1 (es) Anticuerpos que se unen a celulas cancerosas y que dirigen radionucleidos a dichas celulas
CL2018003072A1 (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
PE20200010A1 (es) Anticuerpos que se unen a steap-1
DOP2024000057A (es) Células inmunitarias que tienen arnhc coexpresados y sistemas de compuerta lógica
CL2012003076A1 (es) Anticuerpo aislado que se une a polipeptido antigenico diana asociado a tumores (tat425); celula que lo produce; metodo para identificar un primer anticuerpo que se une a epítopo antigénico tat425; metodo para inhibir el crecimiento de una celula que expresa el polipeptido tat425.
CO2023001413A2 (es) Anticuerpos que se unen a células cancerosas y dirigen radionucleótidos a dichas células
WO2019025865A3 (en) METHODS AND COMPOSITIONS FOR LIGAND-DIRECTED ANTIBODY DESIGN
CO2021013836A2 (es) Modificación de un anticuerpo para la unión selectiva al tumor de cd47
EA201990743A1 (ru) Антитела, направленные против белка-3, содержащего т-клеточный иммуноглобулин и муцин (tim-3)
AR117660A1 (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos
PE20240690A1 (es) Anticuerpos split que se unen a celulas cancerosas y dirigen radionuclidos a dichas celulas